Logo

Alvotech Seeks to End the AbbVie's Wrong Monopoly on Humira and Develops New Biosimilar for Chronic Pain

Share this

Alvotech Seeks to End the AbbVie's Wrong Monopoly on Humira and Develops New Biosimilar for Chronic Pain

Shots:

  • Alvotech has filed a federal lawsuit to end the monopoly on AbbVie’s Humira for taking several improper steps to inflate its patent portfolio includes multiple patents on the same invention and obtain patents through inequitable conduct
  • Alvotech develops AVT02 as a biosimilar of Humira for chronic pain with equal in strength to Humira’s latest formulation and develops AVT02 as an interchangeable product and expects the results from its ongoing interchangeability study in Q2’21
  • The biosimilars are available across EU and in Japan- Canada- and Australia and expect to save US taxpayers and the overall healthcare system of $8-10B annually

  Ref: BUSINESS WIRE | Image: Alvotech 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions